Abstract 194P
Background
In cases of persistent inflammation, the migration of immune cells follow the organogenesis of secondary lymphoid organs (SLO) within the organs, leading to the formation of tertiary lymphoid structures (TLS). These structures have become important as diagnostic and prognostic markers in chronic diseases and cancers. However, there is ongoing debate regarding how to assess the maturation of TLS in tissue samples, both in terms of determining the stages themselves and achieving agreement among pathologists. Based on the composition and organization of TLS revealed through imaging mass cytometry (IMC), we aimed to propose a reproducible classification system consisting of three maturation stages for TLS, which can be applied in pathology practice.
Methods
We used formalin-fixed and paraffin-embedded gastric samples (45 tissues with 134 TLS) and colonic samples (50 tissues with 159 TLS), representing inflammatory, cancerous, and control conditions. These samples were subjected to IMC analysis using a panel of 39 markers. Additionally, we sought correlations between markers that reflect the maturation of TLS (composition and architecture). The two IMC-markers with the strongest correlation with TLS maturation were selected to transfer the TLS maturation staging from IMC to dual-staining immunohistochemistry (IHC). This transfer was done to investigate the level of agreement among pathologists when classifying TLS using a set of 60 tissue IHC images.
Results
Using IMC, we were able to characterize the maturation of TLS and propose three distinct stages: Early TLS, Primary Follicle-Like TLS, and Secondary Follicle-Like TLS, identified as IHC CD21-CD23-, CD21+CD23-, and CD21+CD23+, respectively. The analysis of the 60 dual CD21-CD23 IHC images by three pathologists showed a high level of inter-pathologist agreement in classifying TLS into the three maturation stages (Cohen’s Kappa values: > 0.8).
Conclusions
With a strong correlation to cellular and architectural changes during TLS maturation, the dual CD21-CD23 IHC marker allows for the staging of TLS in tissue samples with a high level of inter-pathologist agreement, which holds potential for prognostic and predictive purposes.
Legal entity responsible for the study
M. Le Rochais.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display